These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prostate cancer screening. Roetzheim RG; Herold AH Prim Care; 1992 Sep; 19(3):637-49. PubMed ID: 1384077 [TBL] [Abstract][Full Text] [Related]
3. How valuable is prostate-specific antigen screening? Handler S Minn Med; 1996 Jun; 79(6):2. PubMed ID: 8692130 [No Abstract] [Full Text] [Related]
4. Is screening for prostate cancer the current gold standard?--"no". Kramer BS; Gohagan JK; Prorok PC Eur J Cancer; 1997 Mar; 33(3):348-53. PubMed ID: 9155515 [No Abstract] [Full Text] [Related]
5. Mass screening for prostate cancer. The Swedish Council on Technology Assessment in Health Care. Int J Cancer Suppl; 1996; 9():1-72. PubMed ID: 8982323 [No Abstract] [Full Text] [Related]
6. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine]. Bourel M; Ardaillou R; Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060 [TBL] [Abstract][Full Text] [Related]
7. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? Rosser CJ; Parker A J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093 [No Abstract] [Full Text] [Related]
8. Screening for prostate cancer: the role of prostate-specific antigen. Ferrer RL Md Med J; 1996 Nov; 45(11):938-40. PubMed ID: 8942171 [No Abstract] [Full Text] [Related]
9. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important? Barry MJ; Mulley AJ J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451 [No Abstract] [Full Text] [Related]
10. PSA and prostate cancer screening: the challenge of the new millennium. Bjartell A Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305 [No Abstract] [Full Text] [Related]
11. Best screening tests for prostate cancer. Moul JW West J Med; 1998 Aug; 169(2):109-10. PubMed ID: 9735692 [No Abstract] [Full Text] [Related]
12. Efficacy vs effectiveness in prostate-specific antigen screening. Albertsen PC J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583 [No Abstract] [Full Text] [Related]
13. [Mass screening for prostate cancer in Nagano]. Ishizuka O; Satoh T; Kobayashi S; Nishizawa O Hinyokika Kiyo; 2001 Nov; 47(11):769-72. PubMed ID: 11771167 [TBL] [Abstract][Full Text] [Related]
14. [Evaluation of mass screening for prostatic cancer]. Nakagawa S Nihon Rinsho; 2002 Dec; 60 Suppl 11():289-93. PubMed ID: 12599587 [No Abstract] [Full Text] [Related]
15. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. Belpomme D; Irigaray P J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186 [No Abstract] [Full Text] [Related]
16. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker. Hamilton RJ; Platz EA; Freedland SJ J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913 [No Abstract] [Full Text] [Related]
18. [Early detection of cancer of the prostate. Pros and cons]. Hoesl CE; Altwein JE MMW Fortschr Med; 2005 Apr; 147(14):32, 34-6. PubMed ID: 15887681 [TBL] [Abstract][Full Text] [Related]
19. A message from preventive medicine and your physician. Prostate cancer. Prev Med; 2000 Aug; 31(2 Pt 1):101-2. PubMed ID: 10938208 [No Abstract] [Full Text] [Related]
20. Is screening for prostate cancer the current gold standard?--"yes". Lange PH Eur J Cancer; 1997 Mar; 33(3):354-6. PubMed ID: 9155516 [No Abstract] [Full Text] [Related] [Next] [New Search]